Nkarta: NK Cell Therapy Advancement On Two Fronts (NASDAQ:NKTX)

Nkarta, Inc. (NASDAQ:NKTX) is gearing up to report results from its phase 1 study, using NKX019 for the treatment of patients with relapsed/refractory non-Hodgkin’s lymphoma [NHL]. Such data is going to be released by mid-2024

Read the full article here